Lane, Roger

Targeting acetylcholinesterase and butyrylcholinesterase in dementia

Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology

Cholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatments

Cited by 654

Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., et al. (2020) · New England Journal of Medicine

Amyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatments

Cited by 565

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Mummery, C. J., Börjesson-Hanson, A., Blackburn, D. J., Vijverberg, E. G. B., De Deyn, P. P., Ducharme, S., Jonsson, M., Schneider, A., Rinne, J. O., Ludolph, A. C., et al. (2023) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 347

Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study

Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C. W., van der Flier, W. M., Hsu, C., Wu, S., & Lane, R. (2008) · Current Medical Research and Opinion

Dementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

Cited by 147

Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial

Edwards, A. L., Collins, J. A., Junge, C., Kordasiewicz, H., Mignon, L., Wu, S., Li, Y., Lin, L., DuBois, J., Hutchison, R. M., et al. (2023) · JAMA Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 113

Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment

Walker, J. R., Van Ameringen, M. A., Swinson, R., Bowen, R. C., Chokka, P. R., Goldner, E., Johnston, D. C., Lavallie, Y.-J., Nandy, S., Pecknold, J. C., et al. (2000) · Journal of Clinical Psychopharmacology

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesSchizophrenia research and treatment

Cited by 84

Design of the First-in-Human study of IONIS-MAPTRx, a Tau-lowering antisense oligonucleotide, in patients with alzheimer disease (S2.006)

Mignon, L., Kordasiewicz, H., Lane, R., Smith, A., Miller, T., Narayanan, P., Swayze, E., Norris, D., Fitzsimmons, B., & Bennett, F. (2018) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 29

Effects of IONIS-HTTRx in Patients with Early Huntington’s Disease, Results of the First HTT-Lowering Drug Trial (CT.002)

Tabrizi, S., Leavitt, B., Kordasiewicz, H., Czech, C., Swayze, E., Norris, D. A., Baumann, T., Gerlach, I., Schobel, S., Smith, A., et al. (2018) · Neurology

Genetic Neurodegenerative DiseasesAmyotrophic Lateral Sclerosis Research

Cited by 26